Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[However, RUNX2 expression was significantly decreased in patients with elevated PSA levels (?20?ng?ml(-1)), a Gleason score ?8 and metastatic disease compared to those with low PSA, low Gleason score and non-metastatic disease (P=0.023, 0.005 and 0.014, respectively).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP828954.RADABzxR1GWDNavLRxwTq54sW_gIkF1zNUE60Yl6a9guI130_assertion description "[However, RUNX2 expression was significantly decreased in patients with elevated PSA levels (?20?ng?ml(-1)), a Gleason score ?8 and metastatic disease compared to those with low PSA, low Gleason score and non-metastatic disease (P=0.023, 0.005 and 0.014, respectively).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP828954.RADABzxR1GWDNavLRxwTq54sW_gIkF1zNUE60Yl6a9guI130_provenance.
• NP641489.RAWz6rukLwZk4ZudeOacs6KRmQM0MZCmnIvd8gjHXB8jE130_assertion description "[However, RUNX2 expression was significantly decreased in patients with elevated PSA levels (?20?ng?ml(-1)), a Gleason score ?8 and metastatic disease compared to those with low PSA, low Gleason score and non-metastatic disease (P=0.023, 0.005 and 0.014, respectively).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP641489.RAWz6rukLwZk4ZudeOacs6KRmQM0MZCmnIvd8gjHXB8jE130_provenance.
• NP318963.RAiZVI-zFHFGnWwcYr7r2Je0KhGXPFUADrwZGrOB2mrcU130_assertion description "[However, RUNX2 expression was significantly decreased in patients with elevated PSA levels (?20?ng?ml(-1)), a Gleason score ?8 and metastatic disease compared to those with low PSA, low Gleason score and non-metastatic disease (P=0.023, 0.005 and 0.014, respectively).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP318963.RAiZVI-zFHFGnWwcYr7r2Je0KhGXPFUADrwZGrOB2mrcU130_provenance.
• NP601301.RA8FM1HK_FL6PkKd2nYkyTkMGv19c1udms2oouJQ_m8jw130_assertion description "[However, RUNX2 expression was significantly decreased in patients with elevated PSA levels (?20?ng?ml(-1)), a Gleason score ?8 and metastatic disease compared to those with low PSA, low Gleason score and non-metastatic disease (P=0.023, 0.005 and 0.014, respectively).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP601301.RA8FM1HK_FL6PkKd2nYkyTkMGv19c1udms2oouJQ_m8jw130_provenance.
• NP614790.RAoeCrdgxu21NddvYuXPCde0P0twnVMNuDWXKJ7E9Huc4130_assertion description "[However, RUNX2 expression was significantly decreased in patients with elevated PSA levels (?20?ng?ml(-1)), a Gleason score ?8 and metastatic disease compared to those with low PSA, low Gleason score and non-metastatic disease (P=0.023, 0.005 and 0.014, respectively).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP614790.RAoeCrdgxu21NddvYuXPCde0P0twnVMNuDWXKJ7E9Huc4130_provenance.
• NP622971.RAjAVGbsJ45iKWTEMk9EtA4IdvpLMgCz3H51Js9vvMKio130_assertion description "[However, RUNX2 expression was significantly decreased in patients with elevated PSA levels (?20?ng?ml(-1)), a Gleason score ?8 and metastatic disease compared to those with low PSA, low Gleason score and non-metastatic disease (P=0.023, 0.005 and 0.014, respectively).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP622971.RAjAVGbsJ45iKWTEMk9EtA4IdvpLMgCz3H51Js9vvMKio130_provenance.
• NP795056.RApB4W2yQm3HnddeWd657OvmM3Grji-o-u1RfeQpgUUxY130_assertion description "[However, RUNX2 expression was significantly decreased in patients with elevated PSA levels (?20?ng?ml(-1)), a Gleason score ?8 and metastatic disease compared to those with low PSA, low Gleason score and non-metastatic disease (P=0.023, 0.005 and 0.014, respectively).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP795056.RApB4W2yQm3HnddeWd657OvmM3Grji-o-u1RfeQpgUUxY130_provenance.
• NP434630.RAG8h344jazGDrWWt9_ZaDYe0KkLa_VlZ3zrNOu6Y6S_U130_assertion description "[However, RUNX2 expression was significantly decreased in patients with elevated PSA levels (?20?ng?ml(-1)), a Gleason score ?8 and metastatic disease compared to those with low PSA, low Gleason score and non-metastatic disease (P=0.023, 0.005 and 0.014, respectively).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP434630.RAG8h344jazGDrWWt9_ZaDYe0KkLa_VlZ3zrNOu6Y6S_U130_provenance.
• NP628343.RAZInpGb3ghLY6DGOAa6G5O8cMzsYOHxmFy6KwkE7yW1c130_assertion description "[However, RUNX2 expression was significantly decreased in patients with elevated PSA levels (?20?ng?ml(-1)), a Gleason score ?8 and metastatic disease compared to those with low PSA, low Gleason score and non-metastatic disease (P=0.023, 0.005 and 0.014, respectively).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP628343.RAZInpGb3ghLY6DGOAa6G5O8cMzsYOHxmFy6KwkE7yW1c130_provenance.
• NP825599.RAZUi3zzqPJLJDnsBZA1J3x1TGLsQSNRT5IeaWvWcat_U130_assertion description "[However, RUNX2 expression was significantly decreased in patients with elevated PSA levels (?20?ng?ml(-1)), a Gleason score ?8 and metastatic disease compared to those with low PSA, low Gleason score and non-metastatic disease (P=0.023, 0.005 and 0.014, respectively).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP825599.RAZUi3zzqPJLJDnsBZA1J3x1TGLsQSNRT5IeaWvWcat_U130_provenance.
• NP648909.RAT2wIMJ-iOfYIkwzz4PfSHk4XSPO7hcMyONtsaMDNGls130_assertion description "[However, RUNX2 expression was significantly decreased in patients with elevated PSA levels (?20?ng?ml(-1)), a Gleason score ?8 and metastatic disease compared to those with low PSA, low Gleason score and non-metastatic disease (P=0.023, 0.005 and 0.014, respectively).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP648909.RAT2wIMJ-iOfYIkwzz4PfSHk4XSPO7hcMyONtsaMDNGls130_provenance.
• NP1004917.RAV8UUwBioiroLBOz1FefQd5xVzDWlk-S7YCGUjEHPs58130_assertion description "[However, RUNX2 expression was significantly decreased in patients with elevated PSA levels (?20?ng?ml(-1)), a Gleason score ?8 and metastatic disease compared to those with low PSA, low Gleason score and non-metastatic disease (P=0.023, 0.005 and 0.014, respectively).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1004917.RAV8UUwBioiroLBOz1FefQd5xVzDWlk-S7YCGUjEHPs58130_provenance.
• NP1004922.RAZrT8IB7DRjcw1g_Y1uhZz85wsoV_CZhFgLP3-joTUa4130_assertion description "[However, RUNX2 expression was significantly decreased in patients with elevated PSA levels (?20?ng?ml(-1)), a Gleason score ?8 and metastatic disease compared to those with low PSA, low Gleason score and non-metastatic disease (P=0.023, 0.005 and 0.014, respectively).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1004922.RAZrT8IB7DRjcw1g_Y1uhZz85wsoV_CZhFgLP3-joTUa4130_provenance.
• NP825715.RAADH8F3rEJmitnB0RbJynYfb9TxqS5gB_u9Eh1PvAyI4130_assertion description "[However, RUNX2 expression was significantly decreased in patients with elevated PSA levels (?20?ng?ml(-1)), a Gleason score ?8 and metastatic disease compared to those with low PSA, low Gleason score and non-metastatic disease (P=0.023, 0.005 and 0.014, respectively).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP825715.RAADH8F3rEJmitnB0RbJynYfb9TxqS5gB_u9Eh1PvAyI4130_provenance.
• NP628499.RArzjokxA3j2tIzNvdkS4jqoAOuwzB4o4qtmWe4aQXMZY130_assertion description "[However, RUNX2 expression was significantly decreased in patients with elevated PSA levels (?20?ng?ml(-1)), a Gleason score ?8 and metastatic disease compared to those with low PSA, low Gleason score and non-metastatic disease (P=0.023, 0.005 and 0.014, respectively).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP628499.RArzjokxA3j2tIzNvdkS4jqoAOuwzB4o4qtmWe4aQXMZY130_provenance.
• NP895355.RAjPtEn1qaVgfNV4-hCF3pEU04pWDSgtiznphYK__IieE130_assertion description "[However, RUNX2 expression was significantly decreased in patients with elevated PSA levels (?20?ng?ml(-1)), a Gleason score ?8 and metastatic disease compared to those with low PSA, low Gleason score and non-metastatic disease (P=0.023, 0.005 and 0.014, respectively).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP895355.RAjPtEn1qaVgfNV4-hCF3pEU04pWDSgtiznphYK__IieE130_provenance.
• NP895237.RAF0KbKY_ayUePsFOaJ4Uvl4HWKK1aTM7QkEjtpic1dJk130_assertion description "[However, RUNX2 expression was significantly decreased in patients with elevated PSA levels (?20?ng?ml(-1)), a Gleason score ?8 and metastatic disease compared to those with low PSA, low Gleason score and non-metastatic disease (P=0.023, 0.005 and 0.014, respectively).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP895237.RAF0KbKY_ayUePsFOaJ4Uvl4HWKK1aTM7QkEjtpic1dJk130_provenance.
• NP649054.RA67RNOkWv2yfpyO3ADvAk8kmZloDqaVPxQ0fSFjXelEc130_assertion description "[However, RUNX2 expression was significantly decreased in patients with elevated PSA levels (?20?ng?ml(-1)), a Gleason score ?8 and metastatic disease compared to those with low PSA, low Gleason score and non-metastatic disease (P=0.023, 0.005 and 0.014, respectively).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP649054.RA67RNOkWv2yfpyO3ADvAk8kmZloDqaVPxQ0fSFjXelEc130_provenance.
• NP1004919.RA5AHhuz8_k8KeC9mlLpN3NJypyRY0Dq5z8_ZYSd9Q5PU130_assertion description "[However, RUNX2 expression was significantly decreased in patients with elevated PSA levels (?20?ng?ml(-1)), a Gleason score ?8 and metastatic disease compared to those with low PSA, low Gleason score and non-metastatic disease (P=0.023, 0.005 and 0.014, respectively).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1004919.RA5AHhuz8_k8KeC9mlLpN3NJypyRY0Dq5z8_ZYSd9Q5PU130_provenance.
• NP1004921.RA34dh_MkTX6dhQEjeZQOBij_UQOwb7zRPbXUhJYuiOhc130_assertion description "[However, RUNX2 expression was significantly decreased in patients with elevated PSA levels (?20?ng?ml(-1)), a Gleason score ?8 and metastatic disease compared to those with low PSA, low Gleason score and non-metastatic disease (P=0.023, 0.005 and 0.014, respectively).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1004921.RA34dh_MkTX6dhQEjeZQOBij_UQOwb7zRPbXUhJYuiOhc130_provenance.
• NP1004923.RA4yLndxW7_Lw6cT-3i22A-THHfXOpZLp1_Av_Iki97yY130_assertion description "[However, RUNX2 expression was significantly decreased in patients with elevated PSA levels (?20?ng?ml(-1)), a Gleason score ?8 and metastatic disease compared to those with low PSA, low Gleason score and non-metastatic disease (P=0.023, 0.005 and 0.014, respectively).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1004923.RA4yLndxW7_Lw6cT-3i22A-THHfXOpZLp1_Av_Iki97yY130_provenance.